Department of General Medicine, Kuala Lipis Hospital, 27200, Kuala Lipis, Pahang, Malaysia.
Department of Pharmacy, Kuala Lipis Hospital, 27200, Kuala Lipis, Pahang, Malaysia.
Int J Clin Pharm. 2019 Oct;41(5):1282-1289. doi: 10.1007/s11096-019-00878-4. Epub 2019 Jul 13.
Background Hyperphosphatemia is a common consequence in end stage renal disease. It is associated with increased cardiovascular risk and mortality, also development of hyperparathyroidism and mineral bone disease. A patient educational program involving physician, pharmacist and dietician was developed to manage hyperphosphatemia among hemodialysis patients. Objective To investigate the efficacy of the program in optimal phosphate control among hemodialysis patients. Setting Kuala Lipis Hospital, Malaysia. Method This was a non-randomized, single-arm community trial running for a period of 6 months. The program consisted of a small group seminar and individual counseling sessions. Two individual counseling sessions were conducted for each patient, focusing on diet and medication adherence, by an accredited dietician and pharmacist respectively. The group seminar was delivered by a multidisciplinary team involving a physician, pharmacist and dietician. Topics included basic knowledge of hyperphosphatemia, phosphate binder and dietary phosphate control. Eligible and consented patients had knowledge and medication adherence assessment, measurement of pre-dialysis serum calcium, albumin, phosphate, haemoglobin and alkaline phosphatase before and after the educational program. Main outcome measure Phosphate level, knowledge and medication adherence assessment. Results Fifty-seven patients completed the program and were included into final data analysis. The median (IQR) phosphate level (mmol/L) was 1.86 (1.45-2.24) before and decreased to 1.47 (1.21-1.91) and 1.49 (1.28-1.81) 3 months and 6 months after PEP (p < 0.001). The percentage of patients with uncontrolled phosphate level was reduced from 59.3 to 35.6% and 42.1% after the PEP (p = 0.003). The mean knowledge score almost doubled after the intervention, with a mean pre-score of 8.61 (95% CI 7.85-9.37) to mean post-score of 15.31 (95% CI 14.85-15.76). The adherence to phosphate binder also improved from 17.2 to 41.4% after PEP (p = 0.007). Conclusion A multidisciplinary patient education program is an effective approach to manage hyperphosphatemia among hemodialysis patients in Malaysia.
高磷血症是终末期肾病的常见后果。它与心血管风险和死亡率的增加有关,也与甲状旁腺功能亢进和矿物质骨病的发展有关。已经开发出一种涉及医生、药剂师和营养师的患者教育计划,以管理血液透析患者的高磷血症。目的:研究该计划在优化血液透析患者磷控制中的疗效。地点:马来西亚瓜拉立卑医院。方法:这是一项非随机、单臂社区试验,持续 6 个月。该计划包括小组研讨会和个别辅导课程。由经过认证的营养师和药剂师分别为每位患者进行两次个别辅导课程,重点是饮食和药物依从性。小组研讨会由医生、药剂师和营养师组成的多学科团队提供。主题包括高磷血症、磷结合剂和饮食磷控制的基础知识。合格并同意参加的患者在教育计划前后进行知识和药物依从性评估、测量透析前血清钙、白蛋白、磷、血红蛋白和碱性磷酸酶。主要结果测量:磷水平、知识和药物依从性评估。结果:57 名患者完成了该计划并纳入最终数据分析。磷水平(mmol/L)中位数(IQR)为 1.86(1.45-2.24),在 PEP 后 3 个月和 6 个月分别降至 1.47(1.21-1.91)和 1.49(1.28-1.81)(p<0.001)。未经控制的磷水平患者比例从 59.3%降至 PEP 后的 35.6%和 42.1%(p=0.003)。干预后,平均知识得分几乎翻了一番,干预前平均得分为 8.61(95%CI 7.85-9.37),干预后平均得分为 15.31(95%CI 14.85-15.76)。磷结合剂的依从性也从 PEP 前的 17.2%提高到 41.4%(p=0.007)。结论:多学科患者教育计划是管理马来西亚血液透析患者高磷血症的有效方法。